Scholarlink

<p>Tumor-associated macrophages (TAMs) are key regulators of immunological responses in tumor microenvironment (TME), exerting a profound impact on cancer progression. The current study aimed to explore TAMs-targeted strategies designed to overcome the immunosuppressive effects and restore antitumor immunity. Our findings demonstrated that selective CDK4/6 inhibitors promote the polarization of M2 macrophages toward the M1 phenotype, which was validated in both in vitro experiments and preclinical tumor models. Concurrently, CDK4/6 inhibitors significantly enhanced the phagocytic capacity of macrophages and activated effector T cell-mediated immune responses. Mechanistically, CDK4/6 inhibitors reduced p53 levels by altering p53 mRNA expression and facilitating its protein degradation. Furthermore, CDK4/6 inhibitor combined with CD47 blockade represents a promising strategy suppressing breast cancer growth. Taken together, our findings unveil a previously unappreciated antitumor mechanism mediated by CDK4/6 inhibition and propose a novel macrophage-based breast cancer immunotherapeutic approach.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting CDK4/6 potentiates the efficacy of anti-CD47 therapy via modulating the suppressive function of tumor-associated macrophages

  • 期刊论文

  • 发表日期：

    2026年6月17日

查看全文
  • Lei Chen,
  • Yue Liu,
  • Nannan Zhu,
  • Han Xie,
  • Tao Zhu,
  • Qianqian Duan,
  • Liang Zhang,
  • Zhao Liu,
  • Xueyan Zhou,
  • Jingshan Tong

摘要

Tumor-associated macrophages (TAMs) are key regulators of immunological responses in tumor microenvironment (TME), exerting a profound impact on cancer progression. The current study aimed to explore TAMs-targeted strategies designed to overcome the immunosuppressive effects and restore antitumor immunity. Our findings demonstrated that selective CDK4/6 inhibitors promote the polarization of M2 macrophages toward the M1 phenotype, which was validated in both in vitro experiments and preclinical tumor models. Concurrently, CDK4/6 inhibitors significantly enhanced the phagocytic capacity of macrophages and activated effector T cell-mediated immune responses. Mechanistically, CDK4/6 inhibitors reduced p53 levels by altering p53 mRNA expression and facilitating its protein degradation. Furthermore, CDK4/6 inhibitor combined with CD47 blockade represents a promising strategy suppressing breast cancer growth. Taken together, our findings unveil a previously unappreciated antitumor mechanism mediated by CDK4/6 inhibition and propose a novel macrophage-based breast cancer immunotherapeutic approach.